Top Markets
Coin of the day
Eli Lilly and Company Eli Lilly and Company

Eli Lilly and Company

LLY
Xếp hạng trong cổ phiếu #14
Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to... Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.
Giá cổ phiếu
$1,133.97
Đồng bộ lần cuối: 2026-09-15
Vốn hóa thị trường
$1.068T
Thay đổi (1 ngày)
-0.39%
Thay đổi (1 năm)
48.29%
Quốc gia
US
Giao dịch Eli Lilly and Company (LLY)

Danh mục

Thu nhập của Eli Lilly and Company (LLY)
Thu nhập trong Jun 2026 TTM: $33.59B
Theo báo cáo tài chính gần đây của Eli Lilly and Company, lợi nhuận hiện tại của công ty là $33.59B. Năm 2024, công ty đạt được lợi nhuận là $12.68B, tăng so với lợi nhuận năm 2023 là $6.55B. Lợi nhuận hiển thị trên trang này là lợi nhuận trước lãi vay và thuế, hay còn gọi là EBIT.
Lịch sử thu nhập của Eli Lilly and Company từ 2000 đến 2026
Thu nhập vào cuối mỗi năm
Năm Thu nhập Thay đổi
2026 (TTM) $33.59B 30.57%
2025 $25.73B 102.91%
2024 $12.68B 93.46%
2023 $6.55B -3.70%
2022 $6.81B 10.57%
2021 $6.16B -14.86%
2020 $7.23B 37.30%
2019 $5.27B 43.09%
2018 $3.68B 59.67%
2017 $2.30B -31.69%
2016 $3.37B 20.93%
2015 $2.79B -7.01%
2014 $3.00B -49.06%
2013 $5.89B 8.90%
2012 $5.41B 1.10%
2011 $5.35B -18.02%
2010 $6.53B 21.79%
2009 $5.36B -509.74%
2008 $-1.31B -133.73%
2007 $3.88B 13.42%
2006 $3.42B 25.78%
2005 $2.72B -7.63%
2004 $2.94B -9.80%
2003 $3.26B -5.67%
2002 $3.46B -2.66%
2001 $3.55B -7.95%
2000 $3.86B 0.00%
Thu nhập của các công ty hoặc đối thủ tương tự
Công ty Thu nhập Chênh lệch thu nhập Quốc gia
$25.20B -25.00%
US
$8.70B -74.11%
US
$21.39B -36.33%
CH
$5.95B -82.29%
US
$16.38B -51.25%
CH